Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180377 | 0.89 | TSHR (0.56) | TSHRPOLBMAPK1LMNAHTT | |
| SCHEMBL4181820 | 0.87 | TSHR (0.55) | TSHRPOLBMAPK1LMNAHTT | |
| SCHEMBL1489970 | 0.86 | TSHR (0.53) | TSHRPOLBMAPK1LMNAHTT | |
| SCHEMBL1489415 | 0.86 | POLB (0.53) | TSHRPOLBMAPK1LMNAHTT | |
| SCHEMBL14120813 | 0.85 | TSHR (0.56) | TSHRPOLBMAPK1LMNAHTT | |
| SCHEMBL4181852 | 0.84 | TSHR (0.51) | TSHRPOLBMAPK1LMNAHTT | |
| SCHEMBL1611607 | 0.84 | TSHR (0.51) | TSHRPOLBMAPK1LMNAHTT | |
| SCHEMBL3365090 | 0.84 | TSHR (0.51) | TSHRPOLBMAPK1LMNAHTT | |
| SCHEMBL1939505 | 0.84 | ALDH1A1 (0.63) | TSHRPOLBMAPK1LMNASMN1; SMN2 | |
| SCHEMBL5012595 | 0.84 | SMN1; SMN2 (0.59) | TSHRPOLBMAPK1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894386-B | 1,2, 3-Triazole compound with IDO1 inhibition function and preparation method thereof | 南开大学 | 2024-10-25 | — | — | CN | claimed |
| CN-109516987-B | Preparation method of avibactam intermediate | 江西富祥药业股份有限公司 | 2020-07-24 | — | — | CN | claimed |
| CN-109516987-A | A kind of AVM hereinafter Batan centre preparation | 江西富祥药业股份有限公司 | 2019-03-26 | — | — | CN | claimed |
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| JP-11292852-A | — | — | None | — | — | JP | disclosed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20260092083-A1 | VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION | RESEARCH TRIANGLE INSTITUTE (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260078132-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | ONCOSPHERIX INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4676533-A1 | VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION | Research Triangle Institute (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-5219848-A | Bactericides | ICI PHARMA (FR) | 1993-06-15 | — | — | US | disclosed |
| EP-0541593-A1 | CYCLOPENTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE. | SCHERING AG (DE) | 1993-05-19 | — | — | EP | disclosed |
| EP-0330910-B1 | PROPANE DERIVATIVES | KOWA COMPANY, LTD. (JP) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992002494-A1 | CYCLOPENTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT BERLIN/BERGKAMEN (DE) | 1992-02-20 | — | — | WO | disclosed |
| US-4960883-A | Cardiovascular disorders | KOWA COMPANY, LTD. (JP) | 1990-10-02 | — | — | US | disclosed |
| US-4948809-A | TREATMENT OF AILMENTS DUE TO THROMBOCYTE AGGREGATION OR KIDNEY DYSFUNCTION | BOEHRINGER MANNHEIM GMBH (DE) | 1990-08-14 | — | — | US | disclosed |
| EP-0330910-A1 | Propane derivatives | KOWA COMPANY, LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4720580-A | N-(aminoalkylene)benzenesulfonamides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | TSHR 1115/4885POLB 3713/4885MAPK1 843/4885 |
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | TSHR 1448/4885POLB 1502/4885MAPK1 1498/4885 |
| US-20260092083-A1 | VANCOMYCIN DERIVATIVES WITH SIDEROPHORE MODIFICATION AS NOVEL REPURPOSED ANTIBIOTICS TO COMBAT GRAM-NEGATIVE BACTERIAL INFECTION | SLC11A2, SLC39A11, SLC39A3 | TSHR 570/4885POLB 3573/4885MAPK1 2722/4885 |
| US-20260078132-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | VHL, HIF1AN, HIF1A | TSHR 3629/4885POLB 1998/4885MAPK1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.